secwatch.observer — SEC 8-K summary
======================================

Issuer:     Revolution Medicines, Inc. (RVMD)
CIK:        0001628171
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0000950170-23-039773
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revolution Medicines Q2 net loss $98.3M; clinical updates for RMC-6236 and RMC-6291
--------------------------------------------------------------------------------

- Net loss of $98.3M vs $61.2M YoY; revenue from Sanofi collaboration $3.8M, down from $9.1M.
- Cash, equivalents and securities $909.5M at June 30, 2023, up from $644.9M at Dec 31, 2022.
- FY 2023 GAAP net loss guidance $360M–$400M; cash expected to fund operations into 2025.
- Planning pivotal single-agent trials for RMC-6236; combination trial with RMC-6291 starting in early 2024.
- Clinical data for RMC-6236 and RMC-6291 to be presented at ESMO and Triple Meeting in October 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628171/000095017023039773/0000950170-23-039773-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628171/000095017023039773/rvmd-20230808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-039773

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer